Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
about
Results and outcome reporting In ClinicalTrials.gov, what makes it happen?Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers.Searching ClinicalTrials.gov and the International Clinical Trials Registry Platform to inform systematic reviews: what are the optimal search approaches?How frequently do the results from completed US clinical trials enter the public domain?--A statistical analysis of the ClinicalTrials.gov database.How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).Clinicaltrials.gov: Is the Glass Half Full?Results availability for analgesic device, complex regional pain syndrome, and post-stroke pain trials: comparing the RReADS, RReACT, and RReMiT databases.Compliance with results reporting at ClinicalTrials.gov.FDAAA legislation is working, but methodological flaws undermine the reliability of clinical trials: a cross-sectional studyAgainst vaccine assay secrecy.Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the Clinicaltrials.gov database.Restoring invisible and abandoned trials: a call for people to publish the findings.Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.Clinical trials: A transparent future for clinical trial reporting.Toward a jurisprudence of drug regulation.Publishing "Invisible" and "Abandoned" clinical trials: a commitment for CTSWhen everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.The use and reporting of patient-reported outcomes in phase III breast cancer trials.Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov.Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).Searching for trial protocols: A comparison of methods.Conflicts of interest, institutional corruption, and pharma: an agenda for reform.Five un-easy pieces of pharmaceutical policy reform.Clinical trial registration and reporting: a survey of academic organizations in the United States.Incomplete and Unreported: Failure to Report Results of Incomplete Studies Results in Publication Bias
P2860
Q28728487-4E00D562-A4AD-4A8B-B209-BAE1394514D3Q30360244-D14AFC9D-E4B9-4CD7-8364-214D25E1CB7BQ33825252-C9E82CD8-0B4D-401F-811B-91B29B5506BFQ33903992-5190BB63-791B-4D29-BF08-8E38E8D14DF4Q34303798-7531072C-6848-43AC-AA60-32B75C0F3684Q34612897-81E41832-9BDB-4E1E-BCD4-42D7A6E4BA43Q34790930-037C4DE8-7B14-4F1C-8A8F-02C1D0D71747Q35575094-D083702D-79FC-49BA-B697-5E96BC323AEAQ35796605-6247B01A-AA4B-415F-BAAC-1D1AFF90641EQ35887486-1C0B5BA3-547F-4327-96FD-6D954EDF8BE5Q35923595-CA92DD5D-94FB-4026-AA59-50BA17113DE2Q36205488-1FA15056-D766-4300-B8B2-BEF57A12D47EQ36937327-9362D149-6E2F-4934-A730-558DBD7CBE95Q38904292-DEA6ACD6-1A8D-469A-802A-C755A080A9A9Q39011096-C3F84EE6-4E9C-4F8B-8E29-3AD362254C4CQ39198481-C2E99FBF-8C51-4A78-BF91-933DAB580600Q42316398-9350B9FE-4A65-4A3A-BAAC-EF20AA70F5B8Q45754296-AEBF58D1-9830-4F49-8D17-5F3FC601F5C1Q46266472-30EA6205-81F1-4636-84ED-6BAD64311FDEQ47717067-250B2AC1-B427-47F0-B15E-355C1E4C6048Q47745738-82410147-BEF5-44E3-A32F-0A8A6847720DQ48094039-4A5A6E10-E0FF-4522-80E5-7DF095733B25Q48373417-07CF530C-14E6-4EB5-B45F-30980BAADFD6Q50146780-03489C73-67EC-41E4-A033-DE3BBF4289F7Q53282847-FAE87DF0-2B37-46DA-95A9-3D7403B46BCDQ58294669-934B0100-06AC-48EF-894D-7C6634726E78
P2860
Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@ast
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@en
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@nl
type
label
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@ast
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@en
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@nl
prefLabel
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@ast
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@en
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@nl
P2093
P1433
P1476
Despite law, fewer than one in ...... on time on ClinicalTrials.gov.
@en
P2093
Michael R Law
Steven G Morgan
Yuko Kawasumi
P304
P356
10.1377/HLTHAFF.2011.0172
P407
P577
2011-12-01T00:00:00Z